MediWound closed at $13.19 on Nov 12, down 4.56%, 31.9% below its 52-week closing high. Volume of 139.4K shares was 0.94× its 20-day average (close to normal).
Split-adjusted performance: +10.7% over one month, -21.5% over six months, -28.8% over one year.
Short interest was 1.8M shares at the Oct 30 settlement, up 2.3% from the prior report (18.6% of float, 14.7 days to cover).
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications.
What is MDWD's market cap?
$189.81M, based on the Nov 12 close of $13.19.
Does MediWound pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MDWD is sold short?
1.8M shares, 18.6% of float, as of Oct 30, 2026.
About MediWound
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
